期刊
JOURNAL OF CLINICAL NEUROSCIENCE
卷 50, 期 -, 页码 292-293出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.jocn.2018.01.064
关键词
CJD; Tau; 14-3-3; CSF
资金
- Commonwealth Department of Health - Australia
- NHMRC Practitioner Fellowship [APP1105784]
The pre-mortem clinical diagnosis of Creutzfeldt-Jakob disease (CJD) is supported by biomarkers, especially cerebrospinal fluid (CSF) 14-3-3 and total tau (Tau) protein levels. These CSF biomarkers have proven the most useful prior to transitioning to powerful next generation diagnostics employing protein amplification techniques such as the real time quaking-induced conversion (RT-QuIC) assay. To enhance national diagnostic capacity while transitioning to RT-QuIC assays an optimized CSF Tau cutoff was determined and shown to usefully supplement 14-3-3 protein detection. (c) 2018 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据